Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prizloncabtagene autoleucel - AbelZeta Pharma

Next Previous
Drug Profile

Prizloncabtagene autoleucel - AbelZeta Pharma

Alternative Names: Anti-CD19 anti-CD20 bispecific chimeric antigen receptor T cell therapy - AbelZeta Pharma; Anti-CD20-Anti CD19-BICAR - AbelZeta Pharma; Autologous second generation CD19/CD20-directed CAR-T cells; C-CAR039; CD19/CD20-directed CAR-T cells; EXP0-039; EXP039; JNJ-4496; JNJ-90014496; Prizlon-cel - AbelZeta Pharma

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group
  • Developer AbelZeta Pharma; Janssen Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action CD137 antigen agonists; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma

Most Recent Events

  • 24 Sep 2025 Prizloncabtagene autoleucel is still in phase I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA, Australia, United Kingdom, Spain, Netherlands, Denmark, Canada, South Korea (IV) (NCT05421663)
  • 13 Jun 2025 Efficacy and adverse events data from a phase I trial in Non-Hodgkin's lymphoma released by Johnson and Johnson
  • 28 Mar 2024 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Australia (IV) (NCT05421663)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top